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Abstract The appearance of vitiligo and spontaneous
regression of the primary lesion in melanoma patients illus-
trate a relationship between tumor immunity and autoim-
munity. T lymphocytes play a major role both in tumor
immunity and autoimmunity. CD28, Cytotoxic T lympho-
cyte antigen 4 (CTLA4) and inducible costimulator (ICOS)
molecules are important secondary signal molecules in the
T lymphocyte activation. Single nucleotide polymorphisms
(SNPs) in the CD28/CTLA4/ICOS gene region were reported
to be associated with several autoimmune diseases includ-
ing, type-1 diabetes, SLE, autoimmune thyroid diseases and
celiac disease. In this study, we investigated the association
of SNPs in the CD28, CTLA4 and ICOS genes with the risk
of melanoma. We also assessed the prognostic eVect of the
diVerent polymorphisms in melanoma patients. Twenty-four
tagging SNPs across the three genes and four additional
SNPs were genotyped in a cohort of 763 German melanoma
patients and 734 healthy German controls. InXuence on
prognosis was determined in 587 melanoma cases belonging
to stage I or II of the disease. In general, no diVerences in
genotype or allele frequencies were detected between mela-
noma patients and controls. However, the variant alleles for
two polymorphisms in the CD28 gene were diVerentially
distributed in cases and controls. Similarly no association of
any polymorphism with prognosis, except for the rs3181098
polymorphism in the CD28 gene, was observed. In addition,
individuals with AA genotype for rs11571323 polymor-
phism in the ICOS gene showed reduced overall survival.
However, keeping in view the correction for multiple
hypothesis testing our results suggest that the polymor-
phisms in the CD28, CTLA4 and ICOS genes at least do not
modulate risk of melanoma and nor do those inXuence the
disease prognosis in the investigated population.
Keywords Melanoma · Polymorphism · CD28/CTLA4/
ICOS · Susceptibility · Prognosis
Introduction
The association between tumor immunity and autoimmu-
nity is complex [1]. Spontaneous regression is believed to
be more common in melanoma than any other cancer types.
However, the eVect of the phenomenon on prognosis is
rather unclear; however, the vitiligo is considered a favor-
able prognostic factor. Autoimmune conditions like thy-
roiditis and vitiligo, induced by interleukin 2 and/or
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Interferon  (IFN) therapy, have been associated with an
improved prognosis in melanoma patients [2,  3]. The
appearance of autoantibodies or autoimmune manifesta-
tions in IFN-treated patients has been reported to be
associated with signiWcantly improved recurrence free and
overall survival [4]. However, the Wndings could not be
replicated when serum samples were analyzed of patients
that were randomized to IFN treatment or observation in
the EORTC 18952 and the Nordic Melanoma Group phase
III trials [5].
T lymphocytes play an important role both in tumor
immunity as well as in autoimmunity. The CD28, cyto-
toxic T lymphocyte antigen 4 (CTLA4) and inducible
co-stimulator (ICOS) molecules are important secondary
signaling molecules involved in the T lymphocyte activa-
tion. The genes encoding CD28, CTL4 and ICOS are
located within a stretch of 300 kb region on chromosome
2q33. Ligation of CD28 molecules with the B7-1 (CD80)
or B7-2 (CD86) on antigen presenting cells (APCs), stim-
ulate T cell activation and proliferation. CTLA4 counter-
balances this eVect by competing with CD28 for B7-1/
B7-2 binding and is therefore an important inhibitor of T
cell activation [6, 7]. CTLA-4 is also an established neg-
ative regulator of T-cell function and proliferation
through multiple mechanisms such as reducing interleu-
kin (IL)-2 and IL-2 receptor productions and arresting
T-cell at the G1-phase of cell cycle [8]. ICOS is another
co-stimulatory molecule which is expressed on activated
T cells. It binds to a unique ligand, ICOSL, and does not
bind to other ligands such as B7-1/B7-2. Polymorphisms
in the CD28/CTLA4/ICOS gene region have been associ-
ated with several autoimmune diseases including, type 1
diabetes, SLE, autoimmune thyroid diseases and celiac
disease [9,  10]. However, a majority of the studies
focused on the known CTLA4 polymorphisms. A high
prevalence of AA genotype for the CT60 polymorphism
in the gene was observed in patients with renal cell can-
cer and a positive correlation between the polymorphism
and tumor grade was also established [11]. The associa-
tion between the variants in the promoter region of the
CTLA4 gene and breast cancer progression has also been
reported [12].
In this study, in order to Wnd an association between
polymorphisms in the CD28, CTLA-4 and ICOS genes and
risk of cutaneous melanoma we screened patients from
Germany and ethnically matched healthy controls. The sin-
gle nucleotide polymorphisms (SNPs) in the three CD28/
CTLA4/ICOS genes were selected by tagging approach in
order to cover the entire gene regions. Additionally four
SNPs reported to be of interest in literature in the CTLA-4
gene were also included in the study. The association of
variants alleles with prognostic outcome was also deter-
mined.
Methods
Patients and controls
The study population consisted of 763 melanoma patients
from Germany (418 male and 345 female), recruited by the
Skin Cancer Unit Mannheim, from 2001 to 2008. Patients
with primary cutaneous melanoma with diVerent disease
stages that included, 10 cases with in situ melanoma, 615
with stage I/II, 111 stage III and 12 cases with stage IV of
the disease. For 15 patients stage was unknown. Disease
staging was performed according to the current AJCC crite-
ria from 2001 [13]. Median and mean age of the melanoma
cases at diagnosis was 55 and 54 years, respectively. Blood
samples from case subjects were taken at their Wrst presen-
tation at the skin cancer unit. DNA was isolated from blood
samples using Qiagen mini-preparation kits. Informed con-
sent was obtained from the patients and the study was
approved by the institutional ethical review board. Control
subjects included 734 healthy German individuals (367
male and 367 female) recruited from blood bank
Mannheim, with mean and median age of 60 and 61 years,
respectively. They were born in southwest Germany and
were matched for ethnicity with cases. The inclusion crite-
ria for controls in the study included cancer free status. The
age diVerence between the cases and controls was statisti-
cally signiWcant (T-test;  P-value <0.01), whereas, the
gender diVerence was not statistically signiWcant (2-test;
P-value >0.05).
Genes and SNPs selection
The selection of polymorphisms in the CD28, CTLA4 and
ICOS genes was based on inclusion of known non-synony-
mous SNPs and those located in regulatory regions as
reported in the dbSNP database of the National Center for
Biotechnology Information, NCBI (http://www.ncbi.nlm.
nih.gov/SNP/) or reported in published papers. Addition-
ally, tagging SNPs from each gene region were selected
from HapMap data using Haploview software 3.32, with
pair-wise r2 > 0.8 for each SNP pair and minor allele fre-
quencies >5% (Fig. 1). Ten tagging SNPs in the CD28
gene, Wve in the CTLA4 gene and 10 in the ICOS gene
were selected from HapMap database that covered three
genes completely. Four polymorphisms, rs11571319
(CT61), rs11571302 (JO31), rs7665213 (JO30) and
rs11571297 (JO27) in the CTLA4 gene, which have been
described to correlate with autoimmune disease(s) were
also selected. The investigated polymorphisms span a
region of 31.0 kb for the CD28 gene region, 6.1 kb for the
CTLA4 gene region and 24.7 kb for the ICOS gene region.
In total, 29 polymorphisms in three genes (CD28, CTLA4
and ICOS) were identiWed.Cancer Immunol Immunother (2010) 59:303–312 305
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Validation of the SNPs by DNA sequencing
The validation of the 29 selected polymorphisms was
carried out by sequencing a set of 32 DNA samples from
control subjects. Sequencing reactions were performed
using Big Dye Terminator Cycle Sequencing Kit (Applied
Biosystems, Foster City, Ca, USA) and the following
conditions were used; initial 94°C for 1 min followed by
27 cycles at 96°C for 16 s, 56°C for 5 s and 60°C for 4 min.
Reaction products were run on ABI prism 3100 Genetic
analyzer (Applied Biosystems). Primers used in PCR
ampliWcation and sequencing reaction are listed in Supple-
mentary Table.
Genotyping
Genotyping of the validated SNPs was performed by allelic
discrimination technique (TaqMan assays, ‘by demand or
design’ Applied Biosystems, Supplementary Table). Geno-
typing for one polymorphism in the ICOS gene (rs4355090)
failed and was, thus, excluded from the study. Genotype
failure rate was 0.14%, calculated from samples that could
not be genotyped after two repeated assays and by direct
DNA sequencing. Genotyping data were conWrmed by ran-
dom direct DNA sequencing of 5% of all samples, which
showed 100% concordance.
Statistical analysis
The association between malignant melanoma and diVerent
genotypes was estimated as odds ratios (OR), 95% conW-
dence intervals (CI) and P-values using SAS version 9.1.
Estimates were adjusted for gender and age. Haplotype pro-
cedure of SAS/Genetics Software was used to calculate
haplotype frequencies in cases and controls. Linkage
disequilibrium (LD) was calculated with Haploview soft-
ware (www.broad.mit.edu/mpg/haploview/documentation.
php). The association between genotypes and diVerent sur-
vival parameters, adjusted for age, gender and Breslow
thickness, was carried out using proportional hazard regres-
sion (Cox) model. Metastases free survival (MFS) was the
time from date of diagnosis until the Wrst metastasis (either
lymph node or distant metastasis) and overall survival (OS)
was time from diagnosis to death. The follow-up of patients
without metastases or who did not decease has been
censored at the latest visit/last contact.
Results
Case-control study
The allelic distribution of polymorphisms in the CD28,
CTLA4 and ICOS genes was assessed in 763 German mel-
anoma patients and compared with 734 healthy German
controls. A total of 28 SNPs were studied and genotype and
allele distributions of all the polymorphisms are summa-
rized in Table 1. Genotype frequency in controls for all the
polymorphisms was in accordance with the Hardy–Weinberg
equilibrium. Minor allele frequency (MAF) for the
rs3181098 polymorphism was higher in cases than in con-
trols (OR: 1.18, 95% CI: 1.00–1.38; P = 0.05). And for the
rs3181100 (C > G) polymorphisms the MAF was lower in
cases than controls (OR: 0.83, 95% CI: 0.71–0.97;
P = 0.02). None of the inferred haplotypes in three genes
showed diVerential distribution between cases and controls
(data not shown).
Association between polymorphisms and prognosis
The association between polymorphisms and survival
parameters was evaluated for melanoma patients in stage I
and II. Information regarding metastases free survival
(MFS), overall survival (OS) and Breslow thickness was
available for 587 patients (321 male and 266 female). Mean
age was 54 years (median 55 years), the mean and median
Breslow thickness was 1.84 and 1.50 mm, respectively.
Ulceration status of the primary tumor was not systemati-
cally recorded in the past and is therefore lacking. Age,
gender and Breslow thickness were included as covariates
in the Cox regression analysis. Overall, on comparing carri-
ers versus non-carriers, no signiWcant diVerences in OS
were observed (Tables 2, 3, 4). A single SNP in the CD28
gene (rs3181098) showed an association with reduced
metastases free survival (HR 1.34 95% CI: 1.02–1.77). In
addition to the carrier versus non-carrier approach, eVect of
the diVerent genotypes on prognosis was analyzed. Accord-
ing to this analysis, one SNP (AA) in the ICOS gene
Fig. 1 Haplotype blocks in the genomic region with CTLA-4, CD28
and ICOS genes based on HapMap data306 Cancer Immunol Immunother (2010) 59:303–312
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Table 1 Case control SNP Genotype Cases 
N =7 6 3
(%) Controls 
N =7 3 4
(%) OR 95% CI P-value
CD28
rs3181098 GG 315 41 331 45
AG 331 43 325 44 1.05 0.84–1.31
AA 117 15 78 11 1.50 1.07–2.11 0.06
G-allele 961 63 987 67
A-allele 565 37 481 33 1.18 1.00–1.38 0.05
rs3181100 CC 279 37 229 31
CG 368 48 357 49 0.87 0.69–1.10
GG 116 15 145 20 0.68 0.50–0.93 0.05
C-allele 926 61 815 56
G-allele 600 39 647 44 0.83 0.71–0.97 0.02
rs3181101 CC 570 75 559 77
CG 175 23 165 23 0.98 0.76–1.26
GG 17 2 7 10 1.97 0.78–4.96 0.35
C-allele 1,315 86 1,283 88
G-allele 209 14 179 12 1.06 0.85–1.33 0.61
rs1181390 GG 474 62 467 64
GT 257 34 233 32 1.14 0.91–1.43
TT 32 4 33 5 0.92 0.55–1.55 0.47
G-allele 1,205 79 1,167 80
T-allele 321 21 299 20 1.06 0.88–1.28 0.53
rs1181388 GG 575 76 545 74
AG 169 22 170 23 0.98 0.76–1.26
AA 17 2 18 3 0.90 0.45–1.81 0.95
G-allele 1,319 87 1,260 86
A-allele 203 13 206 14 0.97 0.78–1.20 0.76
rs17533594 AA 483 63 474 65
AG 257 34 232 32 1.11 0.89–1.40
GG 23 3 24 3 0.94 0.52–1.73 0.63
A-allele 1,223 80 1,180 81
G-allele 303 20 280 19 1.06 0.88–1.28 0.55
rs3116494 AA 414 54 393 54
AG 307 40 299 41 1.01 0.81–1.26
GG 42 6 39 5 1.09 0.67–1.75 0.94
A-allele 1,135 74 1,085 74
G-allele 391 26 377 26 1.02 0.86–1.21 0.79
rs3181107 AA 659 86 620 85
AG 100 13 106 15 0.92 0.67–1.25
GG 4 1 6 1 0.74 0.20–2.79 0.78
A-allele 1,418 93 1,346 92
G-allele 108 7 118 8 0.91 0.68–1.20 0.49
rs3116496 (IVS3 + 17) TT 487 64 475 65
CT 254 33 231 32 1.10 0.88–1.38
CC 22 3 24 3 0.89 0.48–1.64 0.63
T-allele 1,228 81 1,181 81
C-allele 298 20 279 20 1.04 0.86–1.26 0.66Cancer Immunol Immunother (2010) 59:303–312 307
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Table 1 continued SNP Genotype Cases 
N =7 6 3
(%) Controls 
N =7 3 4
(%) OR 95% CI P-value
CTLA4
rs16840252 CC 521 68 489 67 1.00
CT 218 29 222 30 0.91 0.72–1.15
TT 23 3 21 3 1.02 0.54–1.91 0.74
C-allele 1,260 83 1,200 82
T-allele 264 17 264 18 0.95 0.78–1.15 0.57
rs5742909 (CT44) CC 619 81 596 81 1.00
CT 136 18 130 18 0.96 0.73–1.27
TT 8 1 8 1 0.89 0.32–2.49 0.95
C-allele 1,374 90 1,322 90
T-allele 152 10 146 10 0.96 0.75–1.23 0.74
rs231775 (CT42) AA 289 38 283 39 1.00
AG 369 48 345 47 1.08 0.86–1.36
GG 104 14 106 14 0.97 0.70–1.36 0.71
A-allele 947 62 911 62
G-allele 577 38 557 38 1.01 0.87–1.18 0.90
rs231777 CC 539 71 514 70 1.00
CT 208 27 203 28 0.97 0.76–1.23
TT 15 2 16 2 0.83 0.39–1.77 0.87
C-allele 1,286 84 1,231 84
T-allele 238 16 235 16 0.95 0.78–1.17 0.64
rs3087243 (CT60) GG 246 32 223 30 1.00
AG 355 47 388 53 0.81 0.63–1.03
AA 162 21 122 17 1.22 0.89–1.65 0.01
G-allele 847 56 834 57
A-allele 679 45 632 43 1.06 0.91–1.23 0.45
rs11571319 (CT61) GG 518 68 488 67 1.00
AG 222 29 223 31 0.93 0.73–1.17
AA 23 3 21 3 1.02 0.54–1.92 0.81
G-allele 1,258 82 1,199 82
A-allele 268 18 265 18 0.96 0.79–1.16 0.64
rs11571302 (JO31) GG 225 30 210 29 1.00
GT 370 49 383 52 0.87 0.68–1.12
TT 168 22 140 19 1.14 0.84–1.55 0.15
G-allele 820 54 803 55
T-allele 706 46 663 45 1.05 0.90–1.22 0.53
rs7665213 (JO30) GG 228 30 211 29 1.00
AG 370 49 383 52 0.87 0.68–1.12
AA 165 22 137 19 1.13 0.83–1.53 0.17
G-allele 826 54 805 55
A-allele 700 46 657 45 1.04 0.90–1.21 0.59
rs11571297 (JO27) TT 214 28 193 26 1.00
CT 376 49 393 54 0.84 0.65–1.08
CC 173 23 148 20 1.07 0.79–1.45 0.15
T-allele 804 53 779 53
C-allele 722 47 689 47 1.02 0.88–1.18 0.81308 Cancer Immunol Immunother (2010) 59:303–312
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Table 1 continued SNP Genotype Cases 
N =7 6 3
(%) Controls 
N =7 3 4
(%) OR 95% CI P-value
ICOS
rs10932029 (+173) TT 538 71 488 67 1.00
CT 204 27 228 31 0.82 0.65–1.03
CC 21 3 15 2 1.14 0.57–2.27 0.20
T-allele 1,280 84 1,204 82
C-allele 246 16 258 18 0.89 0.73–1.08 0.23
rs4335928 TT 579 76 559 76 1.00
CT 170 22 162 22 0.99 0.77–1.28
CC 14 2 12 2 1.11 0.50–2.47 0.96
T-allele 1,328 87 1,280 87
C-allele 198 13 186 13 1.01 0.80–1.26 0.96
rs4675374 CC 457 60 436 60 1.00
CT 272 36 258 35 0.98 0.78–1.23
TT 34 5 38 5 0.85 0.52–1.40 0.82
C-allele 1,186 78 1,130 77
T-allele 340 22 334 23 0.96 0.80–1.14 0.62
rs7602383 AA 550 72 533 73 1.00
AG 197 26 183 25 1.01 0.79–1.29
GG 16 2 17 2 0.93 0.46–1.90 0.98
A-allele 1,297 85 1,249 85
G-allele 229 15 217 15 0.99 0.81–1.23 0.95
rs4521021 TT 450 59 451 61 1.00
CT 276 36 260 35 1.00 0.80–1.25
CC 37 5 23 3 1.47 0.83–2.60 0.41
T-allele 1,176 77 1,162 80
C-allele 350 23 306 21 1.07 0.89–1.28 0.45
rs11571323 GG 587 77 534 73 1.00
AG 161 21 184 25 0.81 0.63–1.04
AA 15 2 13 2 1.30 0.60–2.84 0.18
G-allele 1,335 88 1,252 86
A-allele 191 13 210 14 0.89 0.71–1.10 0.29
rs12466129 TT 448 59 451 62 1.00
AT 273 36 239 33 1.14 0.91–1.43
AA 42 6 42 6 0,94 0.59–1.51 0.47
T-allele 1,169 77 1,141 78
A-allele 357 23 323 22 1.06 0.89–1.27 0.54
rs10172036 GG 301 40 283 39 1.00
GT 353 46 352 48 0.92 0.73–1.15
TT 109 14 97 13 1.04 0.75–1.45 0.63
G-allele 955 63 918 63
T-allele 571 37 546 37 0.99 0.85–1.16 0.93
rs10183087 AA 461 61 418 57 1.00
AC 263 35 277 38 0.85 0.68–1.06
CC 38 5 37 5 1.04 0.63–1.70 0.32
A-allele 1,185 78 1,113 76
C-allele 339 22 351 24 0.92 0.77–1.10 0.36Cancer Immunol Immunother (2010) 59:303–312 309
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(rs11571323) was associated with reduced overall survival,
P = 0.04, HR 3.60; 95% CI, 1.31–9.91, however, only 13
(2.2%) melanoma patients carried AA genotype.
Discussion
The immunogenic nature of malignant melanoma is clini-
cally manifested by spontaneous regression and appearance
of vitiligo. The phenomenon of autoimmunity observed
during various forms of immunotherapy, IL-2, IFN and
anti-CTLA4 therapy, have been linked to the treatment
response [2–4]. To understand the link between tumor
immunity and autoimmunity in melanoma and to explore
its implication on disease susceptibility and prognosis
remains a challenge [14]. The results from studies evaluat-
ing polymorphisms in various autoimmune diseases sug-
gest the existence of a common autoimmune disease locus
in the CTLA4 gene [9].
We genotyped 28 polymorphisms located in the CD28,
CTLA4 and ICOS genes in melanoma patients and
healthy controls. Use of tagging approach covered the
entire loci for all three genes. To the best of our knowl-
edge, the screen for SNPS in the CTLA4 gene was the
largest ever performed in melanoma patients (and con-
trols) and the Wrst one for the ICOS and CD28 genes. Our
results showed that the variant alleles for two polymor-
phisms in the CD28 gene (rs3181098 and rs3181100)
were diVerentially distributed in cases and controls. No
diVerences in genotype or allele frequencies were
detected between melanoma patients and controls for any
other polymorphism. Similarly, carriers of the variant
allele for the polymorphism rs3181098 in the CD28 gene
showed reduced metastasis free survival and for the poly-
morphism rs11571323 the individuals with variant allele
homozygous genotype were associated with reduced over-
all survival. However, keeping in view the number of tests
carried out in the present study, the observed signiWcant
Table 1 continued SNP Genotype Cases 
N =7 6 3
(%) Controls 
N =7 3 4
(%) OR 95% CI P-value
rs10932036 AA 611 80 594 81 1.00
AT 144 19 129 18 1.09 0.83–1.44
TT 7 1 7 1 1.12 0.37–3.35 0.81
A-allele 1,366 90 1,317 90
T-allele 158 10 143 10 1.08 0.85–1.39 0.53
Table 2 CD28
SNP Genotype Cases (%) 
N =5 8 7
Metastases free survival Overall survival
OR 95% CI P-value OR 95% CI P-value
rs3181098 GG 247 (42)
AG/AA 340 (58) 1.34 1.02–1.77 0.04 1.18 0.81–1.72 0.38
rs3181100 CC 212 (36)
CG/GG 375 (64) 0.82 0.62–1.08 0.16 0.82 0.56–1.20 0.31
rs3181101 CC 440 (75)
CG/GG 146 (25) 1.28 0.94–1.74 0.12 1.21 0.80–1.83 0.38
rs1181390 GG 360 (61)
GT/TT 227 (39) 0.92 0.70–1.21 0.56 1.16 0.80–1.67 0.45
rs1181388 GG 440 (75)
AG/AA 146 (25) 0.86 0.63–1.17 0.32 0.82 0.53–1.25 0.35
rs17533594 AA 372 (63)
AG/GG 215 (37) 1.03 0.78–1.35 0.84 1.23 0.85–1.79 0.28
rs3116494 AA 319 (54)
AG/GG 268 (46) 0.99 0.76–1.30 0.96 1.13 0.79–1.62 0.52
rs3181107 AA 506 (86)
AG/GG 81 (14) 0.81 0.54–1.21 0.30 0.73 0.41–1.29 0.28
rs3116496 (IVS3 +17) TT 378 (64)
CT/CC 209 (36) 1.16 0.88–1.53 0.29 1.39 0.96–2.02 0.08310 Cancer Immunol Immunother (2010) 59:303–312
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associations would be lost upon multiple hypothesis cor-
rection. Moreover, the detected association would also
require conWrmatory testing in an independent population.
One of the limitations of the present study included lack
of pigmentation data, history of sunburns and the existence
of statistical signiWcant diVerence in mean age between
Table 3 CTLA4
SNP Genotype Cases (%) 
N =5 8 7
Metastases free survival Overall survival
OR 95% CI P-value OR 95% CI P-value
rs16840252 CC 399 (68)
CT/TT 187 (32) 1.11 0.84–1.48 0.46 1.25 0.85–1.82 0.26
rs5742909 (CT44) CC 476 (81)
CT/TT 111 (19) 1.24 0.88–1.72 0.22 1.40 0.90–2.18 0.14
rs231775 (CT42) AA 219 (37)
AG/GG 367 (63) 0.99 0.75–1.30 0.93 0.92 0.63–1.33 0.64
rs231777 CC 414 (71)
CT/TT 172 (29) 1.04 0.78–1.39 0.79 1.23 0.83–1.80 0.30
rs3087243 (CT60) GG 195 (33)
AG/AA 392 (67) 0.99 0.74–1.31 0.92 0.93 0.63–1.36 0.69
rs11571319 (CT61) GG 397 (68)
AG/AA 190 (32) 1.10 0.83–1.45 0.51 1.19 0.81–1.73 0.38
rs11571302 (JO31) GG 173 (30)
GT/TT 414 (71) 0.95 0.71–1.27 0.72 0.80 0.55–1.17 0.26
rs7665213 (JO30) GG 176 (30)
AG/AA 411 (70) 0.95 0.72–1.27 0.74 0.83 0.57–1.21 0.32
rs11571297 (JO27) TT 163 (28)
CT/CC 424 (72) 0.87 0.65–1.16 0.33 0.76 0.52–1.11 0.16
Table 4 ICOS
SNP Genotype Cases (%) 
N = 587
Metastases free survival Overall survival
OR 95% CI P-value OR 95% CI P-value
rs10932029 (+173) TT 412 (70)
CT/CC 175 (30) 0.87 0.65–1.17 0.36 0.79 0.53–1.18 0.25
rs4335928 TT 446 (76)
CT/CC 141 (24) 1.17 0.86–1.60 0.32 1.26 0.82–1.92 0.29
rs4675374 CC 352 (60)
CT/TT 235 (40) 1.08 0.82–1.42 0.58 1.31 0.91–1.88 0.15
rs7602383 AA 421 (72)
AG/GG 166 (28) 1.02 0.76–1.37 0.88 1.12 0.75–1.66 0.59
rs4521021 TT 345 (59)
CT/CC 242 (41) 0.96 0.73–1.26 0.77 1.19 0.83–1.71 0.35
rs11571323 GG 452 (77)
AG/AA 135 (23) 1.07 0.78–1.46 0.70 1.27 0.83–1.94 0.28
rs12466129 TT 340 (58)
AT/AA 247 (42) 0.86 0.66–1.13 0.28 1.03 0.72–1.48 0.88
rs10172036 GG 232 (40)
GT/TT 355 (61) 1.12 0.85–1.50 0.42 0.86 0.58–1.26 0.43
rs10183087 AA 352 (60)
AC/CC 234 (40) 0.87 0.66–1.15 0.33 0.93 0.64–1.35 0.70
rs10932036 AA 467 (80)
AT/TT 119 (20) 0.76 0.54–1.06 0.11 0.76 0.48–1.19 0.23Cancer Immunol Immunother (2010) 59:303–312 311
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cases and controls. Keeping in view the fact that ethnicity
and not the age is major determinant of variant allele fre-
quency, in our study design we ensured complete match
between cases and controls for the latter parameter.
Our results are in accordance with a previous study that
reported no diVerence in frequencies of six polymorphisms
in the CTLA4 gene in 203 melanoma patients (stage IIb, IIc
and III), compared to 288 healthy controls. Also no poly-
morphism correlated with improved recurrence free or
overall survival [15]. However, several studies have
reported association of the CTLA4 polymorphisms with
other malignancies [16]. In humans cell CTLA4 exists in
two isoforms, a full-length and a soluble isoform that lacks
exon 3 due to alternative splicing [17]. The CT60 (A/G)
polymorphism in the CTLA4 gene is a key susceptibility
locus for autoimmune diseases, and the G-allele was shown
to be correlated with decreased levels of the soluble iso-
form [9]. The frequency of the AA genotype for CT60
polymorphism was reported to be higher in renal cell carci-
noma (RCC) patients than in controls. In addition, a posi-
tive correlation between the AA genotype and tumor grade
was also observed, suggesting a role in tumor development
[11]. The CT42 polymorphism (49A/G) in exon 1 is the
only amino acid (Thr > Ala) altering polymorphism in the
CTLA4 gene; and the individuals homozygous for the Ala
allele were associated with decreased CTLA4 expression
on the T cell surfaces [18]. The AA genotype was corre-
lated with increased frequencies in RCC patients and the
A allele, in association with the 3-untranslated region
(AT)82 alleles, correlated with non-Hodgkin’s lymphoma
(NHL) [11, 19]. Interestingly, the GG variant was linked to
an increased risk of gastric mucosa-associated lymphoid
tissue (MALT) lymphoma [20]. In a study on multiple can-
cer types, 49A/G polymorphism has been risk of lung,
breast and esophageal cancers as well as gastric cardia [16].
CTLA-4 with variant Thr allele has been shown to be asso-
ciated with stronger inhibitory eVect on T-cell activation
than that with common allele. Polymorphisms in the pro-
moter region of the CTLA4 gene were described to modu-
late expression of the gene [21]. This region contains the
CT44 polymorphism (¡318 C/T) variant. The CC genotype
of the CT44 polymorphism was shown to be correlated
with signiWcantly reduced lymph node involvement in
breast cancer patients [12]. The T allele was linked to an
increased risk of B-CLL but to a decreased risk of MALT
lymphoma [20, 22]. No correlation was found between the
CT44 polymorphism and the risk of colon cancer [23]. The
chromosomal region 2q33 containing the CTLA-4 and
CD28 genes has been linked with asthma, however, the
association with polymorphisms in the genes was not
detected [24].
Melanoma patients with thick primary tumors and/or
nodal involvement are at high risk for relapse or death [13].
However, adjuvant treatment is only beneWcial in a small
group of these patients. Genetic variability possibly pre-
dicts treatment outcome and could be a predictive marker to
select the group beneWting from a certain treatment. In this
study, only stage I and II melanoma patients were evaluated
for a possible association between SNPs and prognosis.
Since these patients do not frequently receive systemic
treatment, we could not assess the predictive value of any
of the polymorphisms. Nevertheless, recently it was shown
that polymorphisms in the CTLA4 gene were correlated
with response in melanoma patients (stage IV) receiving
anti-CTLA4 treatment [25].
In conclusion, from the results of this large study we did
not Wnd convincing evidence for association between poly-
morphisms in the CD28, CTLA4 and ICOS genes and the
risk of melanoma, nor with an eVect on prognosis. Even
two individual polymorphisms showed diVerential distribu-
tion of variant alleles between cases and controls, the eVect
nevertheless was marginal and a chance factor could no be
ruled. The study was conWned to German population, there-
fore, a strong association of polymorphisms investigated
with melanoma susceptibility or disease outcome, in other
populations cannot be entirely precluded.
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